Analysis Of Patient-Reported Outcomes (Pros) For Gog-258, A Randomized Phase Iii Trial Of Cisplatin And Tumor Volume Directed Irradiation Followed By Carboplatin And Paclitaxel (Cis-Rt Plus Cp) Vs. Carboplatin And Paclitaxel (Cp) For Optimally Debulked, Locally Advanced Endometrial Carcinoma: A Gynecologic Oncology Group/Nrg Study.

5589Background: Protocol GOG-258 randomized Cis-RT+CP or CP for 6 cycles to patients (pts) with stage III/IVA endometrial carcinoma (Matei et al, ASCO 2017). Recurrence-free survival was the primary endpoint and was not increased by addition of RT. PRO analyses evaluated the impact of treatment (tx) on quality of life (QOL) during tx and up to 1 year. Methods: PROs were assessed at baseline prior to tx, 6 weeks (wks) after starting tx (corresponding to 1-wk post completion of RT (Cis-RT+CP) or prior to cycle 3 (CP)), and 18 and 70 wks after tx start. The analysis used FACT-En TOI, FACT/GOG-neuropathy (Ntx) subscale, and FACT-C items C3, C5 combined with En1, O1, O3, Cx6 in TOI of FACT-En for gastrointestinal (GI) symptoms (exploratory). Results: Questionnaire compliance was 95% at baseline, 90% at 6 wks, 87% at 18 wks, and 78% at 70 wks after tx start. Pts (332 on Cis-RT+CP and 349 on CP) with valid baseline and ≥ 1 follow-up PRO assessments were evaluable for analysis. After adjusting age and baseline sc...